Acalabrutinib

• Description:

  Acalabrutinib (ACP-196) is an orally available, selective irreversible inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. It is a second generation BTK inhibitor with improved pharmacological properties with better plasma exposure, oral absorption and shorter half-life. It prevents the activation of B-cell antigen receptor (BCR) signaling pathway, thus preventing B-cell activation and BTK mediated activation of downstream survival pathways.

• Shipping Conditions:

  gel pack

• Storage Conditions:

  -20°C

• Shelf Life:

  36 months